{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-003924","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2024-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.107237+00:00","generated_at":"2026-06-06T03:16:36.111290+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Vistagen reports narrower net loss of $6.3M in fiscal Q3; fasedienol trials on track","bullets":["Net loss $6.3M vs $9.8M YoY; cash $126.6M at Dec 31, 2023.","R&D expense $4.5M, down from $6.9M on lower clinical costs.","G&A expense $3.8M, up from $3.1M on compensation.","PALISADE-3 fasedienol trial for SAD initiation expected 1H 2024; PALISADE-4 in 2H 2024.","Preparations underway for itruvone Phase 2B in MDD and PH80 Phase 2B in vasomotor symptoms."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-003924","json":"https://secwatch.observer/filing/0001437749-24-003924.json","markdown":"https://secwatch.observer/filing/0001437749-24-003924.md","text":"https://secwatch.observer/filing/0001437749-24-003924.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000143774924003924/0001437749-24-003924-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000143774924003924/vtgn20240213_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T03:16:36.111290+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"08a9bc3e208410769c0fcd9b2ea54767b8ed3fa9","claim":"Vistagen Therapeutics, Inc. reported fiscal year 2024 third quarter ended December 31, 2023 results: net income $6.3 million.","evidence_excerpt":"Net loss: Net loss was $6.3 million and $9.8 million for the three months ended December 31, 2023, and 2022, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411685/000143774924003924/0001437749-24-003924-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year 2024 third quarter ended December 31, 2023"},{"label":"Net income","value":"$6.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}